Dirk Sauer
Director/Board Member at Iconic Therapeutics, Inc.
Net worth: 8 066 $ as of 2024-05-30
Dirk Sauer active positions
| Companies | Position | Start | End |
|---|---|---|---|
Iconic Therapeutics, Inc.
 Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | Director/Board Member | 2021-04-19 | - |
Career history of Dirk Sauer
Former positions of Dirk Sauer
| Companies | Position | Start | End |
|---|---|---|---|
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 2011-09-30 | 2021-02-28 |
| CALCIMEDICA, INC. | Director/Board Member | 2022-04-12 | - |
| Independent Dir/Board Member | 2022-04-12 | - |
Training of Dirk Sauer
| University of Münster | Undergraduate Degree |
| Philipps University of Marburg | Doctorate Degree |
Statistics
International
| United States | 3 |
| Germany | 3 |
| Switzerland | 2 |
Operational
| Director/Board Member | 2 |
| Undergraduate Degree | 1 |
| Doctorate Degree | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Graybug Vision, Inc.
 Graybug Vision, Inc. Pharmaceuticals: MajorHealth Technology Graybug Vision, Inc. develops ophthalmic drugs. It focus on developing drug delivery therapies for the treatment of eye diseases such as age-related macular degeneration and glaucoma. The company was founded by Justin S. Hanes, Peter John McDonnell, Christy Wyskiel and Peter A. Campochiaro in May 2011 and is headquartered in Redwood City, CA. | Health Technology |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
- Stock Market
- Insiders
- Dirk Sauer
- Experience
